1
B
Koletzko
Diagnostik und Therapie der Hypercholesterinämie bei Kindern und Jugendlichen. Empfehlungen der Arbeitsgemeinschaft für Pädiatrische Stoffwechselstörungen
Monatsschr Kinderheilkd
143
1995
1.041
1.042
2
B
Koletzko
Leitlinien zur Diagnostik und Therapie von Hyperlipidämien bei Kindern und Jugendlichen (APS)
Available from: http://www.aps-med.de/documents/hyperlipid-22-12-2007.pdf
2007
3
ÄZQ
Ä.Z.Q
Beurteilung klinischer Messgrößen des Qualitätsmanagements – Qualitätskriterien und -Indikatoren in der Gesundheitsversorgung
Z Ärztl Fortbild Qualitätssich
5
96
2001
2
15
4
M
Eccles
J
Mason
How to develop cost-conscious guidelines
Health Technol Assess
5
16
2001
1
69
5
EM
Tuzcu
High prevalence of coronary atherosclerosis in asymptomatic teenagers and young adults: evidence from intravascular ultrasound
Circulation
103
22
2001
2.705
2.710
6
A
Joseph
Manifestations of coronary atherosclerosis in young trauma victims – an autopsy study
J Am Coll Cardiol
22
2
1993
459
467
7
HC
McGill
McMahan
Jr
CA
McMahan
Determinants of atherosclerosis in the young. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group
Am J Cardiol
82
10B
1998
30T
36T
8
H
Davies
Atherogenesis and the coronary arteries of childhood
Int J Cardiol
28
3
1990
283
291
9
S
Li
Childhood cardiovascular risk factors and carotid vascular changes in adulthood: the Bogalusa Heart Study
JAMA
290
17
2003
2.271
2.276
10
WP
Newman
3rd
Relation of serum lipoprotein levels and systolic blood pressure to early atherosclerosis. The Bogalusa Heart Study
N Engl J Med
314
3
1986
138
144
11
MJ
Klag
Serum cholesterol in young men and subsequent cardiovascular disease
N Engl J Med
328
5
1993
313
318
12
JP
Strong
The natural history of atherosclerosis in childhood
Ann N Y Acad Sci
623
1991
9
15
13
AW
Zieske
GT
Malcom
JP
Strong
Natural history and risk factors of atherosclerosis in children and youth: the PDAY study
Pediatr Pathol Mol Med
21
2
2002
213
237
14
OT
Raitakari
Cardiovascular risk factors in childhood and carotid artery intima-media thickness in adulthood: the Cardiovascular Risk in Young Finns Study
JAMA
290
17
2003
2.277
2.283
15
HC
Stary
The sequence of cell and matrix changes in atherosclerotic lesions of coronary arteries in the first forty years of life
Eur Heart J
11 Suppl E
1990
3
19
16
B
Koletzko
Störungen des Lipid- und Lipoproteinstoffwechsels
D
Reinhardt
T
Nicolai
KP
Zimmer
Therapie der Krankheiten im Kindes- und Jugendalter
2014
Springer Verlag
Berlin
17
L
Rask-Nissila
Effects of diet on the neurologic development of children at 5 years of age: the STRIP project
J Pediatr
140
3
2002
328
333
18
L
Rask-Nissila
Impact of dietary intervention, sex, and apolipoprotein E phenotype on tracking of serum lipids and apolipoproteins in 1- to 5-year-old children: the Special Turku Coronary Risk Factor Intervention Project (STRIP)
Arterioscler Thromb Vasc Biol
22
3
2002
492
498
19
E
De Franca
JG
Alves
MH
Hutz
Apolipoprotein E polymorphism and its association with serum lipid levels in Brazilian children
Hum Biol
76
2
2004
267
275
20
A
Tammi
Apolipoprotein E phenotype regulates cholesterol absorption in healthy 13-month-old children-The STRIP Study
Pediatr Res
50
6
2001
688
691
21
SR
Daniels
FR
Greer
N
Greer
Committee on, Lipid screening and cardiovascular health in childhood
Pediatrics
122
1
2008
198
208
22
C
Heller
Cerebral venous thrombosis in children: a multifactorial origin
Circulation
108
11
2003
1.362
1.367
23
K
Kurnik
Recurrent thromboembolism in infants and children suffering from symptomatic neonatal arterial stroke: a prospective follow-up study
Stroke
34
12
2003
2.887
2.892
24
R
Marcucci
Increased plasma levels of lipoprotein(a) and the risk of idiopathic and recurrent venous thromboembolism
Am J Med
115
8
2003
601
605
25
LA
Friedman
Sensitivity and specificity of pediatric lipid determinations for adult lipid status: findings from the Princeton Lipid Research Clinics Prevalence Program Follow-up Study
Pediatrics
118
1
2006
165
172
26
S
Tonstad
A rational approach to treating hypercholesterolaemia in children. Weighing the risks and benefits
Drug Saf
16
5
1997
330
341
27
PO
Kwiterovich
Jr
Biochemical, clinical, epidemiologic, genetic, and pathologic data in the pediatric age group relevant to the cholesterol hypothesis
Pediatrics
78
2
1986
349
362
28
Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents; National Heart, Lung, and Blood Institute. Expert panel on integrated guidelines for cardiovascular health and risk reduction in children and adolescents: summary report
Pediatrics
128
Suppl 5
2011
S213
S256
29
MJ
Braamskamp
FA
Wijburg
A
Wiegman
Drug therapy of hypercholesterolaemia in children and adolescents
Drugs
72
6
2012
759
772
30
Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
JAMA
285
19
2001
2.486
2.497
31
GS
Berenson
Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study
N Engl J Med
338
23
1998
1.650
1.656
32
SM
Boekholdt
Association of LDL cholesterol, non–HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis
JAMA
307
12
2012
1.302
1.309
33
J
Goldstein
H
Hobbs
M
Brown
The metabolic and molecular bases of inherited disease
C
Scriver
A
Beaudet
WS
Sly
Familial hypercholesterolemia
2001
McGraw-Hill
New York
2.863
2.913
34
A
van der Graaf
Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children
Circulation
123
11
2011
1.167
1.173
35
NQ
Wu
Acute myocardial infarction in an 8-year old male child with homozygous familiar hypercholesterolemia: laboratory findings and response to lipid-lowering drugs
Clin Lab
59
7–8
2013
901
907
36
D
Brugger
H
Schuster
N
Zollner
Familial hypercholesterolemia and familial defective apolipoprotein B-100: comparison of the phenotypic expression In 116 cases
Eur J Med Res
1
8
1996
383
386
37
U
Loggen
Apolipoprotein B-100 gene mutations and cholesterol control in German patients
Atherosclerosis
166
2
2003
411
412
38
PN
Hopkins
Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hyper-cholesterolemia
J Clin Lipidol
5
3 Suppl
2011
S9
17
39
DA
Leaf
Chylomicronemia and the chylomicronemia syndrome: a practical approach to management
Am J Med
121
1
2008
10
12
40
C
Glaser
Fatty acid composition of serum glycerophospholipids in children
J Pediatr
157
5
2010
826
41
D
Gaudet
Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial
Gene Ther
20
4
2013
361
369
42
AS
Wierzbicki
A
Viljoen
Alipogene tiparvovec: gene therapy for lipoprotein lipase deficiency
Expert Opin Biol Ther
13
1
2013
7
10
43
KE
Berge
Sitosterolemia: a gateway to new knowledge about cholesterol metabolism
Ann Med
35
7
2003
502
511
44
K
Tsubakio-Yamamoto
Current therapy for patients with sitosterolemia-effect of ezetimibe on plant sterol metabolism
J Atheroscler Thromb
17
9
2010
891
900
45
G
Salen
Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia
Circulation
109
8
2004
966
971
46
G
Salen
S
Patel
AK
Batta
Sitosterolemia
Cardiovasc Drug Rev
20
4
2002
255
270
47
M
Drakopoulou
K
Toutouzas
C
Stefanadis
Novel pharmacotherapies of familial hyperlipidemia
Pharmacol Ther
139
3
2013
301
312
48
GF
Watts
Intergrated Guidance on the Care of Familial Hypercholesterolaemia from the International FH Foundation
IJCA
171
3
2013
309
325
49
GF
Watts
Familial hypercholesterolaemia: a model of care for Australasia
Atheroscler Suppl
12
2
2011
221
263
50
GF
Watts
A model of care for familial hypercholesterolaemia: key role for clinical biochemistry
Clin Biochem Rev
33
1
2012
25
31
51
American Diabetes, A., Management of dyslipidemia in children and adolescents with diabetes
Diabetes Care
26
7
2003
2.194
2.197
52
J
Steinberger
Obesity, insulin resistance, diabetes, and cardiovascular risk in children: an American Heart Association scientific statement from the Atherosclerosis, Hypertension, and Obesity in the Young Committee (Council on Cardiovascular Disease in the Young) and the Diabetes Committee (Council on Nutrition, Physical Activity, and Metabolism)
Circulation
107
10
2003
1.448
1.453
53
A
Zimmermann
MM
Weber
Hyperlipoproteinämien
HK
Biesalski
SC
Bischoff
C
Puchstein
Ernährungsmedizin
2010
Thieme
Stuttgart
54
PS
Jellinger
American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis
Endocr Pract
18
Suppl 1
2012
1
78
55
CL
Williams
Cardiovascular health in childhood: A statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association
Circulation
106
1
2002
143
160
56
T
Miida
LDL-cholesterol and HDL-cholesterol concentrations decrease during the day
Ann Clin Biochem
39
Pt 3
2002
241
249
57
SE
Kasim-Karakas
Dietary fat controversy: is it also applicable to children?
Am J Clin Nutr
67
6
1998
1.106
1.107
58
LS
Webber
Tracking of serum lipids and lipoproteins from childhood to adulthood. The Bogalusa Heart Study
Am J Epidemiol
133
9
1991
884
899
59
S
Arslanian
C
Suprasongsin
Insulin sensitivity, lipids, and body composition in childhood: is «syndrome X» present?
J Clin Endocrinol Metab
81
3
1996
1.058
1.062
60
P
Barter
HDL-C: role as a risk modifier
Atheroscler Suppl
12
3
2011
267
270
61
O
Stanger
DACH-LIGA homocystein (german, austrian and swiss homocysteine society): consensus paper on the rational clinical use of homocysteine, folic acid and B-vitamins in cardiovascular and thrombotic diseases: guidelines and recommendations
Clin Chem Lab Med
41
11
2003
1.392
1.403
62
G
Assmann
Implications of emerging risk factors for therapeutic intervention
Nutr Metab Cardiovasc Dis
15
5
2005
373
381
63
CJ
Boushey
A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes
JAMA
274
13
1995
1.049
1.057
64
AJ
Marti-Carvajal
Homocysteine-lowering interventions for preventing cardiovascular events
Cochrane Database Syst Rev
1
2013
65
AD
Sniderman
Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment
Lancet
361
9359
2003
777
780
66
G
Walldius
The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk
Clin Chem Lab Med
42
12
2004
1.355
1.363
67
PJ
Barter
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel
J Intern Med
259
3
2006
247
258
68
AF
Ayyobi
Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia
Arterioscler Thromb Vasc Biol
23
7
2003
1289
1294
69
T
Sveger
K
Nordborg
Apolipoprotein B as a marker of familial hyperlipoproteinemia
J Atheroscler Thromb
11
5
2004
286
292
70
TA
Pearson
Markers of inflammation and cardiovascular disease: application to clinical and public health practi A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association
Circulation
107
3
2003
499
511
71
PM
Ridker
PW
Wilson
SM
Grundy
Should C–reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?
Circulation
109
23
2004
2.818
2.825
72
A
Krebs
Synergistic effects of elevated systolic blood pressure and hypercholesterolemia on carotid intima-media thickness in children and adolescents
Pediatr Cardiol
30
8
2009
1.131
1.136
73
MA
Austin
Genetic causes of monogenic heterozygous familial hypercholesterolemia: a HuGE prevalence review
Am J Epidemiol
160
5
2004
407
420
74
J
O'Loughlin
Usefulness of the American Academy of Pediatrics recommendations for identifying youths with hypercholesterolemia
Pediatrics
113
6
2004
1.723
1.727
75
W
Bao
The relation of parental cardiovascular disease to risk factors in children and young adults. The Bogalusa Heart Study
Circulation
91
2
1995
365
371
76
DM
Kusters
Paediatric screening for hypercholesterolaemia in Europe
Arch Dis Child
97
3
2012
272
276
77
European Association for Cardiovascular Prevention & Rehabilitation
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)
Eur Heart J
32
14
2011
1.769
1.818
78
AM
Al-Shaikh
Impact of the characteristics of patients and their clinical management on outcomes in children with homozygous familial hypercholesterolemia
Cardiol Young
12
2
2002
105
112
79
JH
Stein
Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine
J Am Soc Echocardiogr
21
2
2008
93
111
80
KI
Paraskevas
G
Hamilton
DP
Mikhailidis
Statins: an essential component in the management of carotid artery disease
J Vasc Surg
46
2
2007
373
386
81
S.
Kang
Y
Wu
X
Li
Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta–analysis
Atherosclerosis
177
2
2004
433
442
82
EM
Urbina
Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association
Hypertension
54
5
2009
919
950
83
RJ
Deckelbaum
Preventive nutrition in childhood: a rationale
Public Health Rev
24
2
1996
105
111
84
OS
Descamps
Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization
Atherosclerosis
218
2
2011
272
280
85
BW
McCrindle
Drug therapy of high-risk lipid abnormalities in children and adolescents: a scientific statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, with the Council on Cardiovascular Nursing
Circulation
115
14
2007
1.948
1.967
86
OT
Raitakari
Effects of persistent physical activity and inactivity on coronary risk factors in children and young adults. The Cardiovascular Risk in Young Finns Study
Am J Epidemiol
140
3
1994
195
205
87
RL
Thompson
Dietary advice given by a dietitian versus other health professional or self-help resources to reduce blood cholesterol
Cochrane Database Syst Rev
3
2003
88
PO
Kwiterovich
Safety and efficacy of treatment of children and adolescents with elevated low density lipoprotein levels with a step two diet or with lovastatin
Nutr Metab Cardiovasc Dis
11
Suppl 5
2001
30
34
89
SB
Clauss
PO
Kwiterovich
Long-term safety and efficacy of low-fat diets in children and adolescents
Minerva Pediatr
54
4
2002
305
313
90
B
Koletzko
I
Kupke
U
Wendel
Treatment of hypercholesterolemia in children and adolescents
Acta Paediatr
81
9
1992
682
685
91
H
Lapinleimu
Prospective randomised trial in 1062 infants of diet low in saturated fat and cholesterol
Lancet
345
8948
1995
471
476
92
AM
Tershakovec
Growth of hypercholesterolemic children completing physician-initiated low–fat dietary intervention
J Pediatr
133
1
1998
28
34
93
E
Obarzanek
Safety of a fat-reduced diet: the Dietary Intervention Study in Children (DISC)
Pediatrics
100
1
1997
51
59
94
MS
Jacobson
Heart healthy diets for all children: no longer controversial
J Pediatr
133
1
1998
1
2
95
MS
Jacobson
Normal growth in high-risk hyperlipidemic children and adolescents with dietary intervention
Prev Med
27
6
1998
775
780
96
H
Niinikoski
Prospective randomized trial of low-saturated-fat, low-cholesterol diet during the first 3 years of life. The STRIP baby project
Circulation
94
6
1996
1.386
1.393
97
H
Niinikoski
Impact of repeated dietary counseling between infancy and 14 years of age on dietary intakes and serum lipids and lipoproteins: the STRIP study
Circulation
116
9
2007
1.032
1.040
98
M
Becker
D
Staab
K
Von Bergmann
Treatment of severe familial hypercholesterolemia in childhood with sitosterol and sitostanol
J Pediatr
122
2
1993
292
296
99
JB
Hennermann
Lipid and lipoprotein profiles in children with familial hypercholesterolaemia: effects of therapy
Eur J Pediatr
157
11
1998
912
918
100
M
Sanchez-Bayle
L
Soriano-Guillen
Influence of dietary intervention on growth in children with hypercholesterolaemia
Acta Paediatr
92
9
2003
1.043
1.046
101
N
Shafiq
Dietary treatment for familial hypercholesterolaemia
Cochrane Database Syst Rev
1
2010
102
PM
Kris-Etherton
DS
Taylor
G
Zhao
Is there an optimal diet for the hypertriglyceridemic patient?
J Cardiovasc Risk
7
5
2000
333
337
103
JA
Carson
Nutrition therapy for dyslipidemia
Curr Diab Rep
3
5
2003
397
403
104
PO
Kwiterovich
Jr
Dyslipoproteinemia and other risk factors for atherosclerosis in children and adolescents
Atherosclerosis
108
Suppl
1994
55
71
105
Efficacy and safety of lowering dietary intake of fat and cholesterol in children with elevated low-density lipoprotein cholesterol
The Dietary Intervention Study in Children (DISC). The Writing Group for the DISC Collaborative Research Group
JAMA
273
18
1995
1.429
1.435
106
CS
O'Gorman
MB
O'Neill
LS
Conwell
Considering statins for cholesterol-reduction in children if lifestyle and diet changes do not improve their health: a review of the risks and benefits
Vasc Health Risk Manag
7
2011
1
14
107
KV
Porkka
OT
Raitakari
Serum lipoproteins in children and young adults: determinants and treatment strategies
Curr Opin Lipidol
7
4
1996
183
187
108
JM
Silva
The triglyceride lowering effect of fish oils is affected by fish consumption
Int J Cardiol
57
1
1996
75
80
109
DC
Chan
Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity
Am J Clin Nutr
77
2
2003
300
307
110
VM
Montori
Fish oil supplementation in type 2 diabetes: a quantitative systematic review
Diabetes Care
23
9
2000
1.407
1.415
111
M
Rouis
Therapeutic response to medium-chain triglycerides and omega-3 fatty acids in a patient with the familial chylomicronemia syndrome
Arterioscler Thromb Vasc Biol
17
7
1997
1.400
1.406
112
SS
Gidding
Dietary recommendations for children and adolescents: a guide for practitioners: consensus statement from the American Heart Association
Circulation
112
13
2005
2061
2075
113
CK
Roberts
AK
Chen
RJ
Barnard
Effect of a short-term diet and exercise intervention in youth on atherosclerotic risk factors
Atherosclerosis
191
1
2007
98
106
114
TJ
Starc
Greater dietary intake of simple carbohydrate is associated with lower concentrations of high-density-lipoprotein cholesterol in hypercholesterolemic children
Am J Clin Nutr
67
6
1998
1.147
1.154
115
American Academy of Pediatrics Steering Committee on Quality, I. and Management, Classifying recommendations for clinical practice guidelines
Pediatrics
114
3
2004
874
877
116
R
Talati
The comparative efficacy of plant sterols and stanols on serum lipids: a systematic review and meta-analysis
J Am Diet Assoc
110
5
2010
719
726
117
H
Gylling
MA
Siimes
TA
Miettinen
Sitostanol ester margarine in dietary treatment of children with familial hypercholesterolemia
J Lipid Res
36
8
1995
1.807
1.812
118
MA
Hallikainen
ES
Sarkkinen
MI
Uusitupa
Plant stanol esters affect serum cholesterol concentrations of hypercholesterolemic men and women in a dose-dependent manner
J Nutr
130
4
2000
767
776
119
AL
Amundsen
Plant sterol ester-enriched spread lowers plasma total and LDL cholesterol in children with familial hypercholesterolemia
Am J Clin Nutr
76
2
2002
338
344
120
KG
Moruisi
W
Oosthuizen
AM
Opperman
Phytosterols/stanols lower cholesterol concentrations in familial hypercholesterolemic subjects: a systematic review with meta-analysis
J Am Coll Nutr
25
1
2006
41
48
121
O
Guardamagna
Primary hyperlipidemias in children: effect of plant sterol supplementation on plasma lipids and markers of cholesterol synthesis and absorption
Acta Diabetol
48
2
2011
127
133
122
H
Gylling
The effects of plant stanol ester consumption on arterial stiffness and endothelial function in adults: a randomised controlled clinical trial
BMC Cardiovasc Disord
13
2013
50
123
I
Garaiova
Effect of a plant sterol, fish oil and B vitamin combination on cardiovascular risk factors in hypercholesterolemic children and adolescents: a pilot study
Nutr J
12
2013
7
124
A
Kim
Green tea catechins decrease total and low-density lipoprotein cholesterol: a systematic review and meta-analysis
J Am Diet Assoc
111
11
2011
1.720
1.729
125
XX
Zheng
Green tea intake lowers fasting serum total and LDL cholesterol in adults: a meta-analysis of 14 randomized controlled trials
Am J Clin Nutr
94
2
2011
601
610
126
L
Cai
The effect of coffee consumption on serum lipids: a meta-analysis of randomized controlled trials
Eur J Clin Nutr
66
8
2012
872
877
127
B
Wittenstein
Plasma antioxidants in pediatric patients with glycogen storage disease, diabetes mellitus, and hypercholesterolemia
Free Radic Biol Med
33
1
2002
103
110
128
MM
Engler
Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial
Circulation
108
9
2003
1.059
1.063
129
DP
Vivekananthan
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials
Lancet
361
9374
2003
2.017
2.023
130
Lowering blood homocysteine with folic acid based supplements. meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration
BMJ
316
7135
1998
894
898
131
Q
Yang
Improvement in stroke mortality in Canada and the United States, 1990 to 2002
Circulation
113
10
2006
1.335
1.343
132
YM
Smulders
HJ
Blom
The homocysteine controversy
J Inherit Metab Dis
34
1
2011
93
99
133
NJ
Farpour-Lambert
Physical activity reduces systemic blood pressure and improves early markers of atherosclerosis in pre-pubertal obese children
J Am Coll Cardiol
54
25
2009
2.396
2.406
134
K
Tolfrey
AM
Jones
IG
Campbell
The effect of aerobic exercise training on the lipid-lipoprotein profile of children and adolescents
Sports Med
29
2
2000
99
112
135
LL
Hayman
Cardiovascular health promotion in the schools: a statement for health and education professionals and child health advocates from the Committee on Atherosclerosis, Hypertension, and Obesity in Youth (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association
Circulation
110
15
2004
2.266
2.275
136
L
Erhardt
Cigarette smoking: an undertreated risk factor for cardiovascular disease
Atherosclerosis
205
1
2009
23
32
137
BG
Nordestgaard
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
Eur Heart J
34
45
2013
3.478
3.490
138
L
Assouline
Familial hypercholesterolemia: molecular, biochemical, and clinical characterization of a French-Canadian pediatric population
Pediatrics
96
2 Pt 1
1995
239
246
139
KE
Sorensen
Impairment of endothelium–dependent dilation is an early event in children with familial hypercholesterolemia and is related to the lipoprotein(a) level
J Clin Invest
93
1
1994
50
55
140
S
Tonstad
Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects
Arterioscler Thromb Vasc Biol
16
8
1996
984
991
141
BM
Rifkind
B
Schucker
DJ
Gordon
When should patients with heterozygous familial hypercholesterolemia be treated?
JAMA
281
2
1999
180
181
142
J
Rodenburg
Statin treatment in children with familial hypercholesterolemia: the younger, the better
Circulation
116
6
2007
664
668
143
RE
Kavey
Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American Heart Association Expert Panel on Population and Prevention Science; the Councils on Cardiovascular Disease in the Young, Epidemiology and Prevention, Nutrition, Physical Activity and Metabolism, High Blood Pressure Research, Cardiovascular Nursing, and the Kidney in Heart Disease; and the Interdisciplinary Working Group on Quality of Care and Outcomes Research: endorsed by the American Academy of Pediatrics
Circulation
114
24
2006
2.710
2.738
144
A
van der Graaf
Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia
J Am Coll Cardiol
52
17
2008
1421
1429
145
S
Clauss
Ezetimibe treatment of pediatric patients with hypercholesterolemia
J Pediatr
154
6
2009
869
872
146
EA
Stein
Colesevelam hydrochloride: efficacy and safety in pediatric subjects with heterozygous familial hypercholesterolemia
J Pediatr
156
2
2010
231
236
147
C
Baigent
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
Lancet
366
9493
2005
1.267
1.278
148
P
Jones
Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)
Am J Cardiol
81
5
1998
582
587
149
SM
Grundy
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
Circulation
110
2
2004
227
239
150
EA
Stein
Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial
JAMA
281
2
1999
137
144
151
VG
Athyros
AA
Papageorgiou
AG
Kontopoulos
Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia
Atherosclerosis
163
1
2002
205
206
152
S
de Jongh
Family history of cardiovascular events and endothelial dysfunction in children with familial hypercholesterolemia
Atherosclerosis
163
1
2002
193
197
153
S
de Jongh
Early statin therapy restores endothelial function in children with familial hypercholesterolemia
J Am Coll Cardiol
40
12
2002
2.117
2.121
154
A
Dirisamer
The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation
Eur J Pediatr
162
6
2003
421
425
155
BW
McCrindle
L
Ose
AD
Marais
Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo–controlled trial
J Pediatr
143
1
2003
74
80
156
A
Wiegman
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial
JAMA
292
3
2004
331
337
157
M
Hedman
Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study
J Clin Endocrinol Metab
90
4
2005
1.942
1.952
158
SB
Clauss
Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia
Pediatrics
116
3
2005
682
688
159
HJ
Avis
A systematic review and meta-analysis of statin therapy in children with familial hypercholesterolemia
Arterioscler Thromb Vasc Biol
27
8
2007
1.803
1.810
160
E
Argent
Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients
Pediatr Transplant
7
1
2003
38
42
161
MG
Penson
Safety and efficacy of pravastatin therapy for the prevention of hyperlipidemia in pediatric and adolescent cardiac transplant recipients
J Heart Lung Transplant
20
6
2001
611
618
162
CS
O'Gorman
MF
Higgins
MB
O'Neill
Systematic review and metaanalysis of statins for heterozygous familial hypercholesterolemia in children: evaluation of cholesterol changes and side effects
Pediatr Cardiol
30
4
2009
482
489
163
N
Shafiq
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia
Int J Clin Pharmacol Ther
45
10
2007
548
555
164
A
Vuorio
Statins for children with familial hypercholesterolemia
Cochrane Database Syst Rev
7
2010
165
C
Arambepola
Statin treatment for children and adolescents with heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis
Atherosclerosis
195
2
2007
339
347
166
Y
Saito
Pitavastatin: an overview
Atheroscler Suppl
12
3
2011
271
276
167
KB
Hoffman
A survey of the FDA’s AERS database regarding muscle and tendon adverse events linked to the statin drug class
PLoS One
7
8
2012
e42866
168
RJ
Edison
M
Muenke
Mechanistic and epidemiologic considerations in the evaluation of adverse birth outcomes following gestational exposure to statins
Am J Med Genet A
131
3
2004
287
298
169
A
Wiegman
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia
Lancet
363
9406
2004
369
370
170
H
Meyer zu Schwabedissen
HK
Kroemer
[Ezetimib]
Dtsch Med Wochenschr
129
39
2004
2.038
2.040
171
T
Sudhop
Inhibition of intestinal cholesterol absorption by ezetimibe in humans
Circulation
106
15
2002
1.943
1.948
172
F
Ezzet
The plasma concentration and LDL-C relationship in patients receiving ezetimibe
J Clin Pharmacol
41
9
2001
943
949
173
M
Harris
W
Davis
WV
Brown
Ezetimibe
Drugs Today (Barc)
39
4
2003
229
247
174
RH
Knopp
Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies
Int J Clin Pract
57
5
2003
363
368
175
D
Yeste
Ezetimibe as monotherapy in the treatment of hypercholesterolemia in children and adolescents
J Pediatr Endocrinol Metab
22
6
2009
487
492
176
CM
Ballantyne
Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial
Circulation
107
19
2003
2.409
2.415
177
C
Gagne
Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia
Circulation
105
21
2002
2.469
2.475
178
K
Winkler
Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus
Atherosclerosis
220
1
2012
189
193
179
CA
Liacouras
Use of cholestyramine in the treatment of children with familial combined hyperlipidemia
J Pediatr
122
3
1993
477
482
180
JR
Guyton
AC
Goldgerg
Bile acid sequestrants
CM
Ballantyne
Clinical lipidology: a companion to Braunwald’s heart disease
2009
Saunders, Elsevier
Philadelphia
281
314
181
S
Tonstad
The C677T mutation in the methylenetetrahydrofolate reductase gene predisposes to hyperhomocysteinemia in children with familial hypercholesterolemia treated with cholestyramine
J Pediatr
132
2
1998
365
368
182
BW
McCrindle
Acceptability and compliance with two forms of cholestyramine in the treatment of hypercholesterolemia in children: a randomized, crossover trial
J Pediatr
130
2
1997
266
273
183
R
McPherson
Comparative effects of simvastatin and cholestyramine on plasma lipoproteins and CETP in humans
Can J Clin Pharmacol
6
2
1999
85
90
184
CM
Perry
Colesevelam: in pediatric patients with heterozygous familial hypercholesterolemia
Paediatr Drugs
12
2
2010
133
140
185
S
Tonstad
Efficacy and safety of cholestyramine therapy in peripubertal and prepubertal children with familial hypercholesterolemia
J Pediatr
129
1
1996
42
49
186
S
Tonstad
Low dose colestipol in adolescents with familial hypercholesterolaemia
Arch Dis Child
74
2
1996
157
160
187
MH
Davidson
A systematic review of bile acid sequestrant therapy in children with familial hypercholesterolemia
J Clin Lipidol
5
2
2011
76
81
188
MJ
Braamskamp
Management of Hypercholesterolemia in Children
Paediatr Drugs
2014
2010
189
National Cholesterol Education Program Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report
Circulation
106
25
2002
3.143
3.421
190
M
Becker
D
Staab
K
Von Bergman
Long-term treatment of severe familial hypercholesterolemia in children: effect of sitosterol and bezafibrate
Pediatrics
89
1
1992
138
142
191
DL
Tribble
Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia
Metabolism
57
6
2008
796
801
192
L
Brunton
J
Lazo
K
Parker
The Pharmacological Basis of Therapeutics
11th Edition ed.
2005
New York
Goodman & Gilman’s
193
H
Bays
Rationale for prescription omega-3-acid ethyl ester therapy for hypertriglyceridemia: a primer for clinicians
Drugs Today (Barc)
44
3
2008
205
246
194
MM
Engler
Docosahexaenoic acid restores endothelial function in children with hyperlipidemia: results from the EARLY study
Int J Clin Pharmacol Ther
42
12
2004
672
679
195
BG
Nordestgaard
Lipoprotein(a) as a cardiovascular risk factor: current status
Eur Heart J
31
23
2010
2.844
2.853
196
RB
Colletti
Niacin treatment of hypercholesterolemia in children
Pediatrics
92
1
1993
78
82
197
J
Thiery
D
Seidel
LDL-apheresis: clinical experience and indications in the treatment of severe hypercholesterolemia
Transfus Sci
14
3
1993
249
259
198
G
Kropshofer
Plasmapheresis as treatment for transient iatrogenic severe hyperlipidemia in a child with leukemia
Med Pediatr Oncol
41
2
2003
177
199
F
Blessing
The efficacy and safety of the new heparin-induced extracorporeal low-density lipoprotein precipitation system (Plasmat Futura) in comparison with the currently used system (Plasmat Secura)
Ther Apher Dial
8
1
2004
33
38
200
D
Seidel
H.E.L.P. apheresis therapy in the treatment of severe hypercholesterolemia: 10 years of clinical experience
Artif Organs
20
4
1996
303
310
201
C
Stefanutti
The lipid- and lipoprotein- [LDL-Lp(a)] apheresis techniques. Updating
G Chir
33
11–12
2012
444
449
202
LC
Hudgins
Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia
Am J Cardiol
102
9
2008
1.199
1.204
203
GR
Thompson
H.-U.L.A.W. Group
Recommendations for the use of LDL apheresis
Atherosclerosis
198
2
2008
247
255
204
A
Goldammer
Atorvastatin in low-density lipoprotein apheresis-treated patients with homozygous and heterozygous familial hypercholesterolemia
Metabolism
51
8
2002
976
980
205
MM
Page
Lipoprotein apheresis and new therapies for severe familial hypercholesterolemia in adults and children
Best Pract Res Clin Endocrinol Metab
28
3
2014
387
403
206
GK
Hovingh
Diagnosis and treatment of familial hypercholesterolaemia
Eur Heart J
34
13
2013
962
971
207
C
Gelsinger
E
Steinhagen-Thiessen
U
Kassner
Therapeutic potential of mipomersen in the management of familial hypercholesterolaemia
Drugs
72
11
2012
1.445
1.455
208
FDA approves new orphan drug Kynamro to treat inherited cholesterol disorder. FDA NEWS RELEASE 2013 [cited 2014 14.01.2014]
Available from: http://www.fda.gov/NewsEvents/-Newsroom/PressAnnouncements/ucm337195.htm
209
D
Noto
AB
Cefalu
MR
Averna
Beyond statins: new lipid lowering strategies to reduce cardiovascular risk
Curr Atheroscler Rep
16
6
2014
414
210
MJ
Gutierrez
Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol-Lowering Therapy for the Treatment of Patients with Hypercholesterolemia and Type 2 Diabetes Mellitus
Arterioscler Thromb Vasc Biol
2014
211
CM
Ballantyne
Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo–controlled, parallel–group trial
J Am Coll Cardiol
62
13
2013
1.154
1.162